A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory merkel cell carcinoma.

被引：0
|
作者：
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard E.
Miller, David M.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Surg, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [22] Salvage nivolumab plus ipilimumab after prior PD-1/PD-L1 inhibitor treatment in metastatic renal cell carcinoma: A meta-analysis.
    Yin Ming
    Mori-Vogt, Sherry
    Hinkley, Megan
    Parikh, Anish B.
    Yang Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li Mingjia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [24] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [25] Effect of NK cell treatment on PD-L1 expression and anti-PD-L1 response
    Copik, Alicja
    Oyer, Jeremiah
    Gitto, Sarah
    Altomare, Deborah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] IMMUNOTHERAPY Benefit with anti-PD-L1
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 70 - 70
  • [27] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [28] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [29] Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study
    Bravo, P.
    Vss, B.
    Baldini, C.
    Romano, P. Martin
    Hollebecque, A.
    Varga, A.
    Vuagnat, P.
    Champiat, S.
    Marabelle, A.
    Escudier, B.
    Albiges, L.
    Loriot, Y.
    Massard, C.
    Cataldi, A.
    Babai, S.
    Voisin, A-L.
    Lambotte, O.
    Annereau, M.
    Michot, J-M.
    ANNALS OF ONCOLOGY, 2019, 30 : 18 - 18
  • [30] Successful Radiation Therapy with Avelumab-Reinduction in Patients with PD-1/PD-L1-refractory Merkel Cell Carcinoma
    Gellrich, F. F.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 27 - 27
12345